In this study we measured the binding parameters of different apolipoprotein (apo) B-containing lipoproteins to the low density lipoprotein (LDL) receptor of HeLa cells. Our goal was to determine the respective roles of the different apolipoproteins of these particles, with particular emphasis on apos B, E, and C-II1. Very low density lipoprotein from hypertriglyceridemic subjects (B to E molar ratio=l:16) bound to HeLa cells with an affinity higher than that of LDL, but the apparent number of binding sites per cell was lower. Because of the heterogeneity of these lipoproteins, which were isolated by ultracentrifugation, we used immunoaffinity chromatography to define these particles on the basis of their apolipoprotein content. Lipoprotein B (LpB) particles that contained apo B as their sole apolipoprotein had lower affinity for the LDL receptor than did total LDL but had an apparently higher number of binding sites. The presence of apo E of phenotype E3/E3 or E4/E4 on one particle increased the affinity of the apo B-containing lipoprotein for the LDL receptor. The apparent number of binding sites decreased, probably due to the fact that a lipoprotein particle containing multiple copies of apo E bound to more than one molecule of LDL receptor. Interaction with several LDL receptors would also explain the higher binding affinity that we observed. The calculated number of binding sites expressed for each apo E molecule is close to the number of binding sites for lipoproteins containing only apo B (LpB or LDL), indicating that each apo E can interact with one LDL receptor. When the apo E phenotype was E2/E2, the LpB: E lipoproteins did not bind to the LDL receptor. A similar result was obtained with the LpB: C-III particles. These data suggest that apos E and C-III impaired the interaction of apo B with the LDL receptor. It is likely that in LpB: E, only apo E (in the case of E3/E3 or E4/E4 phenotype) participates in the LDL receptor binding. (Arteriosclerosis and Thrombosis 1991;11:1021-1029)
A polipoproteins (apos) B-100 and E bind specif-/ \ ically to low density lipoprotein (LDL) re-A. X . ceptors. In in vitro studies apo E-rich lipoproteins such as high density lipoprotein c (HDL,.) 1 or /3-very low density lipoproteins (/3-VLDLs) are shown to bind to the LDL receptor with an affinity 20 times higher than that of LDL itself. 12 The higher capacity of hypertriglyceridemic very low density lipoprotein (VLDL) 3 to compete with LDL for receptor binding has also been attributed to the apo E content of these lipoproteins. Several authors have studied the binding of apo E-containing dimyristoyl phosphatidylcholine (DMPC) vesicles to the LDL receptor. 4 These reconstituted particles bind avidly to the receptor when apo E3 is used. Innerarity et al s also demonstrated that apo E2 can attain full binding activity by the removal of the carboxyl-terminal third of the molecule and the addition of a positive charge at residue 158. 5 Apo B binding seems to be affected by the triglyceride content of lipoproteins, as demonstrated by Aviram et al. 6 They suggested that the conformation of the B protein on large triglyceride-rich particles may be altered.
Studies of apo B catabolism have shown that the protein in human VLDL and LDL is kinetically heterogeneous. This heterogeneity relates mainly to the variation in apolipoprotein content, size, and density. 7 " 10 The hepatic removal of VLDL B,E is faster than that of VLDL B. On the other hand, light LDL is cleared from the circulation more effectively than is heavy LDL through processes mediated by LDL receptors. reconstitution in vitro. Different authors have demonstrated that it is possible to obtain lipoproteins by immunoaffinity chromatography by the use of monoclonal or polyclonal antibodies. 12 Anti-apolipoprotein immunoadsorbants preserve the structural integrity of lipoprotein particles and in particular avoid the dissociation that is commonly seen during ultracentrifugation of apo E-containing lipoproteins. 13 The present study was designed to assess the respective roles of apos B and E in the lipoproteinreceptor interaction when they are present together on the same particle. HeLa cells were used because they specifically bind, internalize, and degrade LDL by a receptor-mediated pathway.
14 Lipoproteins were obtained by ultracentrifugation and sequential immunoaffinity chromatography.
The present article focuses on the binding characteristics of lipoproteins containing only apo B (LpB) or containing apos B,E and/or C-III (LpB:E, LpB:C-III:E, and LpB:C-III). We also examine the influence of size and apo E phenotype.
Because there is one apo B per particle, we expressed the results in relation to the number of moles of bound apo B. Direct binding studies were used to avoid the apolipoprotein exchanges that are always possible in competition studies.
Methods

Plasma and Lipoproteins
Lipoproteins were isolated from human blood samples obtained from normolipidemic or hypertriglyceridemic subjects. The samples were collected in Vacutainer tubes containing Na 2 EDTA at a final concentration of 50 /u,M. After separation of the plasma by low-speed centrifugation at 4°C, the following cocktail of preservatives was added: 0.6 mM chloramphenicol, 1.6 mM glutathione, 10 mM caproic acid, and 1 mM chloromethyl ketone. The plasma was immediately used for the isolation of lipoproteins by immunoaffinity chromatography or ultracentrifugation.
Ultracentrifugation Procedures
Human VLDLs {d< 1.006 kg/1) and LDL (d= 1.030-1.055 kg/1) were isolated from plasma by sequential ultracentrifugation. 15 Lipoprotein-deficient serum (d> 1.21 kg/1) was prepared from a pool of fresh serum by subjecting this material to two centrifugation steps at 100,000g for 24 hours at 4°C.
Isolation of Lipoprotein Particles by Immunoaffinity Chromatography
Antibodies against apos E, C-III, (a), and LDL were raised in rabbits and then purified by affinity chromatography on columns containing the appropriate antigen covalently coupled to CNBr-activated Sepharose 4B according to the procedure of the manufacturer (Pharmacia Fine Chemicals, Uppsala, Sweden).
1617 Affinity-isolated antibodies were then covalently coupled to CNBr-activated Sepharose 4B (10 mg/ml wet gel). Forty milliliters of fresh plasma was diluted to 200 ml with tris(hydroxymethyl)aminomethane (Tris) buffer (0.01 M Tris HC1, 0.15 M NaCl, 0.3 mM EDTA, 1.5 mM NaN 3 , and 10 /AM phenylmethylsulfonyl fluoride, pH 8) and passed down the anti-apo B column at a flow rate of 60 ml/hr. Lipoproteins that did not bind to the immunosorbent were washed off with the Tris buffer, and nonspecifically bound proteins were removed by washing the gel with the same buffer containing 0.5 M NaCl. These fractions were tested for apolipoproteins by enzyme-linked immunosorbent assay. 18 The complex apo B-containing particles, which remained bound to the column, were eluted with 3 M sodium thiocyanate (50 ml). A column of Sephadex G25 (100 ml, Pharmacia) was linked to the immunosorbent column to immediately separate the lipoproteins from the dissociating agent (sodium thiocyanate).
The mixture of complex apo B-containing particles eluted from the anti-apo B column was incubated with an anti-apo(a) immunosorbent. The unbound particles were washed from the immunosorbent as described above. These unretained particles were then incubated with anti-apo E and/or anti-apo C-III immunosorbent, and lipoprotein fractions LpB, LpB:E, and LpB:C-III were obtained according to the scheme presented in Figure 1 .
Gel Filtration of Lipoprotein Particles
The size distribution of the lipoprotein particles was determined by gel filtration, as described by Ha and Barter, 19 When no value is quoted, the particle size is that of LDL. Large LpBs were LpBs of VLDL size, and small LpBs were LpBs of LDL size.
Apolipoprotein Quantification
The content of apos(a), A-I, A-II, B, E, and C-III was checked by specific noncompetitive enzyme immunoassay. 18 - 20 Lipoprotein particles were assumed to contain one molecule of apo B per particle, 21 -22 and molar ratios were calculated after assuming a molecular weight of 550,000 for apo B, 34,000 for apo E, and 8,500 for apo C-III. A given apolipoprotein was considered to be absent when its molar ratio to apo B was less than 0.10.
Apolipoprotein E Phenotypes
Apo E phenotypes were determined from total plasma according to Menzel and Utermann 23 by use of a monoclonal antibody against apo E. 
Lipid Analysis
Total cholesterol, free cholesterol, triglycerides, and phospholipids were measured by specific enzymatic test kits from Boehringer Mannheim, Mannheim, FRG. Esterified cholesterol was estimated as the difference between total cholesterol and free cholesterol.
Cell Culture
HeLa cells were grown in Dulbecco's modified Eagle's medium containing penicillin (100 units/ml), streptomycin (100 /ig/ml), and 10% (vol/vol) fetal calf serum in 30-mm-diameter multidish plates. When they were nearly confluent, the cells were transferred for 48 hours to a medium containing 10% (vol/vol) lipoprotein-deficient serum.
Lipoprotein Labeling
Lipoproteins were radiolabeled with iodine-125-labeled Nal (Amersham, Irvine, UK) by the iodine monochloride method of MacFarlane. 25 The specific radioactivity is expressed in cpm per nanogram and is indicated in the figure or table legends (average of 300 cpm/ng protein).
Monolayer Binding Studies
Binding studies of 125 I-labeled lipoproteins were performed (on nearly confluent cells) at 4°C to avoid endocytosis, as described by Goldstein and Brown. 26 Six different concentrations of labeled lipoproteins were incubated in triplicate with cells in a final volume of 0.7 ml Dulbecco's modified Eagle's medium. Nonspecific binding was determined by adding a 20-fold excess of unlabeled LDL to the binding assay system. These assays were performed in triplicate. The dissociation constant K D and the apparent LP B : E : C-lll number of binding sites per cell (N) were calculated by Scatchard's method. 27 K D was expressed in nanomoles per liter of particles, and N was determined from the number of particles bound per milligram cell protein (about 2xlO 6 cells/mg) after assuming that there is one apo B in each lipoprotein particle (apo B M r =550,000). When the apo E affinity was calculated, we used 34,000 as its molecular weight.
Other Techniques
Cellular protein was determined by the method of Lowry et al. 28 DMPC-apo E liposomes were prepared according to the method of Roth et al, 4 as modified by Jonas et al. 29 
Results
Low Density Lipoprotein Binding to HeLa Cells
The LDLs (d=1.030-1.053 kg/1) from 16 different normolipidemic donors were used in each experiment. The K D and the apparent number of binding sites per cell were determined. The mean for the K D was 12.75±3.2xl0" 9 M, and for N, 42,400±7,000. The greater imprecision for N than for K D is due to nonspecific binding. The small variation of apo C-HI and E composition of LDL did not seem to contribute significantly to variations in K D and N. (There is always less than one apo C-IH or E for one apo B.) The reproducibility of the method was good.
Lipoprotein B Binding to HeLa Cells
LpB particles isolated from whole plasma varied in size. Most particles eluted by gel filtration were in the LDL size range, while some particles had the same elution volume as VLDL, intermediate density lipoprotein, or even HDL (Figure 2 (LDL size) represented, on average, 78% of the LpB. Total LpB particles bound to the LDL receptor with a lower affinity (K D =20.2±4.6 nM) than did LDL, but the apparent number of binding sites (77,320 ±11,700) on the cells was higher (Figure 3 ). Small LpB particles separated from large LpB particles by gel filtration were assayed for binding to HeLa cells. The equilibrium parameters of small particles for binding to the LDL receptor (K u =24 nM and N=60,000) were not significantly different from those obtained with total LpB. This was not surprising, considering that small particles represented the majority of LpB particles. The same measurement for large LpB particles (VLDL size -2% of the particles) gave a high nonspecific binding that did not permit accurate calculation of the apparent number of binding sites; however, the K u for large LpB (^D=20.5 nM) was not significantly different from the K D for total LpB.
Role of Apolipoproteins E and C-III in the Binding of Lipoprotein Particles to HeLa Cells
Binding to HeLa cells of lipoproteins isolated by sequential ultracentrifugation. Table 1) . The results are expressed in terms of moles of apo B, assuming that there is only one apo B per lipoprotein particle. This approach, of course, does not take into account those lipoproteins without apo B. Because VLDL represents a mixture of lipoproteins with different apolipoprotein contents, we used affinity-purified lipoproteins in the further experiments.
LpB.E and LpB:E:C-III binding to HeLa cells. LpB:E isolated from different subjects had a variable apo E content. (The apo E content was three or fewer molecules per particle.) Higher apo E to B ratios were found in LpB:E:C-HI. The binding curve of LpB:E (molar ratio B to E=l:3) is shown in Figure 3 . These particles had a lower capacity but a higher affinity of binding to HeLa cells than did LpB and LDL. Equilibrium parameters for LpB:E and LpB:E:C-III are given in Table 2 
FIGURE 4. Curves showing specific binding of lipoproteins isolated by sequential ultracentrifugation to the low density lipoprotein (LDL) receptors of HeLa cells. HeLa cells preincubated for 48 hours in medium containing 10% (vol/vol) lipoprotein-deficient serum were incubated for 2 hours at 4°C with different concentrations of iodine-125-labeled lipoproteins (LDL, -A-[389 cpm/ng]; I25 I-N VLDL [VLDL obtained from normolipidemic subject, -m-[366 cpm/ng]; and 125 I-VLDL HTG (VLDL obtained from hyperlipidemic subject, -Q-[210 cpm/ng]) alone (total binding) or with a 20-fold excess ofunlabeled LDL (nonspecific binding). Data points shown represent mean specific binding of triplicate assays and were calculated from the difference between total binding and nonspecific binding. Scatchard analysis of the data is plotted in inset. VLDL, very low density lipoprotein, HTG, hypertriglyceridemic.
E content in one particle led to enhanced affinity for the LDL receptor unless there was only one apo E per particle, in which case the LpB:E (molar ratio, 1:1) did not behave differently from LpB.
LpB:E2/E2 (molar ratio of apo B to apo E = l :3.7) was prepared from a type III dyslipoproteinemic patient. It had a reduced binding affinity for cellular receptors, so that a Scatchard plot could not be constructed despite the presence of apo B in the particles. That could explain the in vivo accumulation of particles containing apo E2. In contrast, LpB: E4/E4 (molar ratio of apo B to apo E = l : l ) had normal cellular receptor-binding activity when compared with LDL from normal subjects but had a higher affinity than did LpB.
The presence of apo C-III could inhibit particle affinity for the receptor because LpB:E:C-III containing six apo Es and six apo C-IIIs per particle exhibited the same binding features as did LpB:E with three apo Es per particle.
LpB.C-lIIbinding to HeLa cells. Specific binding of LpB:C-III (nine apo C-IIIs per particle) was negligi- Values are mean+SD. Each lipoprotein was purified by sequential affinity chromatography. K D and N (apparent number of binding sites per cell for one lipoprotein) were calculated by Scatchard's method and expressed per lipoprotein particle, after assuming one apo B per particle. Apo E phenotype was always E3/E3 except where indicated.
Apo, apolipoprotein; Lp, lipoprotein; n, number of different preparations.
ble (Figure 3 ), but the particle LpB:E:C-III (with 20 apo Es and 13 apo C-IIIs) had an apparent high affinity for the receptor (K D =0.75 nM), and the apparent number of receptor sites was very low. Therefore, apo C-III (in LpB:C-III) appears to inhibit the apo B binding to the LDL receptor, but apo C-III (in LpB:C-III:E) does not change to any extent the binding to the receptor. Affinity of LpB.E calculated in relation to the apolipoprotein E content. When the dissociation constant and the number of binding sites was calculated not for the apo B content but in relation to the apo E content and expressed in terms of binding affinity of one apo E, we found that as the apo E content of VLDL, LpB:E, or LpB:C-III:E rose, the K D decreased ( Figure 5) ; however, we did not see any significant variation in the number of binding sites per cell for the apo E molecule. The number of binding sites (62,495 ±12,500) was close to that found for LDL or LpB when calculated on the basis of apo B, suggesting that only one apo E or one apo B binds to each receptor molecule. nM 3 0 - 
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FIGURE 5. Plot showing variation ofKo (nM) in relation to the apo Elapo B content of lipoproteins when Kj, was expressed as the affinity of each apo E molecule. The Scatchard plots were constructed by using values for bound apo E (frnol apo E/mg cell protein) and free apo E (pmol apo E/ml). Apo, apolipoprotein.
ng DMPC-apo E/ml
FIGURE 6. Line plot of dimyristoyl phosphatidylcholine (DMPC) -apo E binding to HeLa cells. Iodine-125 -labeled DMPC-apo E (204 cpm/ng) was added to the cells alone (-O-) or with a 20-fold excess ofunlabeled LDL (-*•). The amount of specific binding (-•-) was calculated as the difference between total binding and nonspecific binding (in the presence ofunlabeled LDL). Scatchard plot is shown as inset. Apo, apolipoprotein; LDL, low density lipoprotein.
Dimyristoyl phosphatidylcholine-apolipoprotein E binding to HeLa cells. DMPC-apo E, synthetic particles of HDL size but of discoidal form, had a molar ratio of phospholipids to apo E of 2.45 (weight ratio of 125). Binding curves and Scatchard plots ( Figure 6 ) revealed that these particles possessed a high affinity for LDL receptors (K D =IA nM) and that the apparent number of binding sites for apo E was optimal (N=195,000) and four times higher than that for apo E included in LpB:E particles. Thus, one particle containing multiple apo E ligands but no apo B seems to bind to several binding sites on the same receptor molecule.
Discussion
Apos B and E both interact with cellular LDL receptors, but their respective contributions to the process in vivo are not clearly known. The recently established kinetic heterogeneity of lipoprotein density classes results from the complexity of apolipoprotein composition within the operationally defined lipoproteins. 30 Consequently, it is difficult to express particle binding results according to their apolipoprotein content. Because there is one apo B per particle and only one apo B can bind to one receptor, we expressed the results of the present study in terms of moles of apo B. However, in VLDL some lipoproteins (LpE or LpC-III:E) do not contain apo B.
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This led us to use lipoprotein particles isolated by immunoaffinity chromatography and defined by their apolipoprotein content. We studied the interaction in vitro of apo B-containing lipoprotein particles on HeLa cells.
Examination of the interaction of these particles with HeLa cells suggests that one lipoprotein containing a sole apo B apparently occupies a high number of binding sites. The apparent number of receptors for LpB was higher than that for LDL, and the affinity was lower. Because LpB contains a single apo B per particle, its size must vary only according to its changing lipid content. We therefore separated large and small LpB to verify if lipids influenced the LpB binding affinity for the receptor. Particles of both sizes possessed a similar affinity for the LDL receptor. Zechner et al 31 also presumed that the greater the apo B content other than B, the weaker is the particle's affinity for the receptor. We showed that apo C-III when present diminished the binding of apo B-containing lipoproteins, suggesting strongly that apo C-III acts as an inhibitor of lipoprotein binding. This agrees with the hypothesis of Ginsberg et al, 32 who deduced that apo C-III has such a role from their in vivo study of subjects with apo C-III deficiency. Recent results from Russel et al 33 indicated that all the cysteine-rich repeats from 3 to 7 are required for the binding of apo B to the LDL receptor and that deletion of any one of these repeats markedly reduced LDL binding. This feature suggests that the binding interaction domain of apo B-100 with the LDL receptor must be very large and sensitive to surrounding proteins.
Then we studied lipoproteins LpB:E and LpB:C-III:E. In such lipoproteins two ligands could interact with the LDL receptor: apo B, or apo E if the apo E phenotype was not E2/E2. We found that LpB:E2/E2 as LpB:C-III did not bind to the receptor. This suggests that, as in the case of apo C-III, apo E decreases apo B accessibility to the receptor. For lipoproteins containing E3/E3 or E4/E4 (Table 2) , their affinity for the receptor was increased with the quantity of apo E per particle (Table 2 ). However, a single apo E on a particle had no striking effect on its binding capacity. For these particles two binding parameters have been studied: the apparent number of binding sites and the apparent dissociation constant. We successively examined the results for each parameter. It was demonstrated that when several apo Es were together on a lipoprotein particle (LpB:E and LpB:C-IH:E), the apparent number of binding sites for these particles decreased with regard to the number of apo E molecules per particle but did not significantly change when the binding parameters were calculated per apo E molecule. The model of interaction with the LDL receptor could be as follows. One apo B interacts with one molecule of LDL receptor, and one apo E interacts with one molecule of LDL receptor, but a lipoprotein containing multiple copies of apo E interacts with several LDL receptor molecules (one for each apo E) and thus decreases the apparent number of binding sites for that type of lipoprotein. This result is not obtained with the DMPC-apo E particles, for which the apparent number of binding sites per apo E is higher. These particles are smaller, and Russel et al 33 have recently demonstrated that in one molecule of LDL receptor several repeats can interact with several copies of apo E. We suggest that this can occur with small particles such as DMPC-apo E but not with large particles such as LpB:E or LpB:C-III:E. We also demonstrated a higher affinity of the lipoprotein particles (including one apo B and several apo E) when the apo E content increased. This result is consistent with the interaction of one lipoprotein with several LDL receptor molecules (one for each apo E). If this hypothesis is true when the K D is expressed for the apo E molecule, we should have the same affinity of each apo E for the LDL receptor. We observed ( Figure 5 ) a higher affinity of each apo E molecule when the lipoprotein contained multiple copies of apo E; this suggests a cooperative effect in the apo E binding. However, even when lipoprotein particles are isolated by immunoaffinity we must remember that the apo E content per particle is a mean value and that the apparent K D is also a mean value; this comment is particularly important for VLDL, whose heterogeneity is greater and which includes particles with and without apo E.
Our results support other findings 8 showing that in vivo the number of apo E molecules on lipoproteins containing apo B is a major determinant of their clearance and has a profound influence on the conversion of VLDL particles to lipoproteins of higher density (intermediate density lipoproteins and LDL). We have not been able to isolate from normal or hypertriglyceridemic plasma LpB:E particles with a high apo E content as have been obtained for LpB:C-III:E. This may be so either because such particles do not exist in the plasma or they are cleared rapidly from the circulation.
Further research, including studies of the biologic expression of apo E on particles with different sizes and studies of the availability of theses lipoproteins, is needed to estimate their relative contribution in the metabolism of these particles. A further in vivo study of the metabolism of these particles is necessary to confirm these in vitro interactions.
